Suppr超能文献

针对 COVID-19 感染的新兴治疗策略。

Emerging treatment strategies for COVID-19 infection.

机构信息

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.

Division of Brain Sciences, Imperial College London, London, UK.

出版信息

Clin Exp Med. 2021 May;21(2):167-179. doi: 10.1007/s10238-020-00671-y. Epub 2020 Oct 30.

Abstract

The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused by SARS-CoV-2 characterized as atypical pneumonia. As of July 1, 2020, more than 10 million people worldwide had been infected with SARS-CoV-2. The typical manifestations of COVID-19 include fever, sore throat, fatigue, cough, and dyspnoea combined with recent exposure. Most of the patients with COVID-19 have mild or moderate disease, however up to 5-10% present with severe and even life-threatening disease course. The mortality rates are approximately 2%. Therefore, there is an urgent need for effective and specific antiviral treatment. Currently, supportive care measures such as ventilation oxygenation and fluid management remain the standard of care. Several clinical trials are currently trying to identify the most potent drug or combination against the disease, and it is strongly recommended to enroll patients into ongoing trials. Antivirals can be proven as safe and effective only in the context of randomized clinical trials. Currently several agents such as chloroquine, hydroxychloroquine, favipiravir, monoclonal antibodies, antisense RNA, corticosteroids, convalescent plasma and vaccines are being evaluated. The large numbers of therapeutic interventions aim to define the most efficacious regimen. The aim of this article is to describe the treatment strategies that have been used for COVID-19 patients and review all the available literature.

摘要

新型冠状病毒(COVID-19),SARS-CoV-2 起源于中国武汉,已导致全球大流行。COVID-19 是一种由 SARS-CoV-2 引起的新型突发传染病,表现为非典型性肺炎。截至 2020 年 7 月 1 日,全球已有超过 1000 万人感染 SARS-CoV-2。COVID-19 的典型表现包括发热、咽痛、乏力、咳嗽和呼吸困难,并伴有近期暴露史。大多数 COVID-19 患者为轻症或中度,然而高达 5-10%的患者病情严重,甚至危及生命。死亡率约为 2%。因此,急需有效的、特异的抗病毒治疗。目前,通气氧疗和液体管理等支持性治疗措施仍是标准治疗方法。目前正在进行多项临床试验,以确定针对该疾病最有效的药物或联合用药,强烈建议患者参加正在进行的临床试验。只有在随机临床试验中,才能证明抗病毒药物的安全性和有效性。目前正在评估氯喹、羟氯喹、法匹拉韦、单克隆抗体、反义 RNA、皮质类固醇、恢复期血浆和疫苗等几种药物。大量的治疗干预措施旨在确定最有效的方案。本文旨在描述已用于 COVID-19 患者的治疗策略,并回顾所有现有文献。

相似文献

1
Emerging treatment strategies for COVID-19 infection.
Clin Exp Med. 2021 May;21(2):167-179. doi: 10.1007/s10238-020-00671-y. Epub 2020 Oct 30.
3
Possible treatment and strategies for COVID-19: review and assessment.
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. doi: 10.26355/eurrev_202012_24057.
4
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Adv Chronic Kidney Dis. 2020 Sep;27(5):434-441. doi: 10.1053/j.ackd.2020.09.001. Epub 2020 Sep 17.
5
Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
SLAS Discov. 2021 Mar;26(3):311-329. doi: 10.1177/2472555220979579. Epub 2020 Dec 15.
6
Treatment options for COVID-19: The reality and challenges.
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
7
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Arch Microbiol. 2021 Jul;203(5):2043-2057. doi: 10.1007/s00203-021-02183-z. Epub 2021 Feb 8.
8
Gender differences in treatment of Coronavirus Disease-2019.
Monaldi Arch Chest Dis. 2020 Dec 3;90(4). doi: 10.4081/monaldi.2020.1508.
9
Treatment of SARS-CoV-2: How far have we reached?
Drug Discov Ther. 2020 May 6;14(2):67-72. doi: 10.5582/ddt.2020.03008. Epub 2020 Apr 25.
10
COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Virol Sin. 2020 Dec;35(6):685-698. doi: 10.1007/s12250-020-00297-0. Epub 2020 Sep 30.

引用本文的文献

1
Predictors of Impaired Treatment Outcomes in COVID-19: A Single-Center Observational Study from Serbia.
Diagnostics (Basel). 2025 Jul 2;15(13):1685. doi: 10.3390/diagnostics15131685.
2
Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis.
Br J Clin Pharmacol. 2025 May;91(5):1306-1321. doi: 10.1002/bcp.70025. Epub 2025 Mar 6.
3
Low dose of hydroxychloroquine is associated with reduced COVID-19 mortality: a multicenter study in China.
Front Med. 2025 Apr;19(2):386-390. doi: 10.1007/s11684-025-1123-9. Epub 2025 Mar 4.
5
Use of CRP/lymphocyte ratio as a predictor of treatment selection and mortality in COVID-19 patients in the intensive care unit.
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241303331. doi: 10.1177/03946320241303331.
6
Serum transgelin is a novel prognostic biomarker for COVID-19 patients.
Front Immunol. 2024 Nov 29;15:1423182. doi: 10.3389/fimmu.2024.1423182. eCollection 2024.
7
An in-depth exploration of snake venom-derived molecules for drug discovery in advancing antiviral therapeutics.
Heliyon. 2024 Sep 2;10(18):e37321. doi: 10.1016/j.heliyon.2024.e37321. eCollection 2024 Sep 30.
10
COVID-19: from immune response to clinical intervention.
Precis Clin Med. 2024 Jul 18;7(3):pbae015. doi: 10.1093/pcmedi/pbae015. eCollection 2024 Sep.

本文引用的文献

1
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
3
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
4
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
5
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19.
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454. doi: 10.1093/cid/ciaa954.
6
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
7
The Emerging Role of Convalescent Plasma in the Treatment of COVID-19.
Hemasphere. 2020 May 21;4(3):e409. doi: 10.1097/HS9.0000000000000409. eCollection 2020 Jun.
8
Identification of pathophysiological patterns for triage and respiratory support in COVID-19.
Lancet Respir Med. 2020 Aug;8(8):752-754. doi: 10.1016/S2213-2600(20)30279-4. Epub 2020 Jun 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验